Matinas BioPharma Holdings (MTNB) said Monday that the European Medicines Agency has recommended its cryptococcosis therapeutic candidate, MAT2203, for...
Health care stocks were mostly lower this afternoon, with the NYSE Health Care Index sinking 1.6% while the SPDR Health Care Select Sector ETF (XLV) was...
Health care stocks were declining premarket Monday. The Health Care SPDR (XLV) was down 0.22% and the iShares NASDAQ Biotechnology Index (IBB) was recently...
BioNTech SE (BNTX) and Matinas BioPharma Holdings, Inc. (MTNB) said Monday that they have signed an exclusive research agreement to evaluate the...
| Address | 1545 Route 206 South Bedminster, New Jersey 07921-9999 |
| Phone | +1.908.484.8805 |
| Number of Employees | 15 |
| Recent SEC Filing | 08/11/2022 10-Q |
| President, Chief Executive Officer & Director | Jerome D. Jabbour |
| Chief Financial Officer | Keith A. Kucinski |
| Chief Scientific Officer & Senior Vice President | Raphael J. Mannino |
| Chief Medical Officer | James J. Ferguson |
| Price Open | $0.80 |
| Previous Close | $0.77 |
| 52 Week Range | $0.49 - 1.61 |
| Market Capitalization | $167.0 M |
| Shares Outstanding | 216.9 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major | Next Earnings Announcement | 11/14/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$0.12 |
| Beta vs. S&P 500 | N/A |
| Revenue | $119.8 K |
| Net Profit Margin | -2,394.06% |
| Return on Equity | -50.55% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
